Carlyle Group has agreed to pay $435m for the biologics research technology provider, which has raised $86m from investors including Novo.
Pharmaceutical firm Novo is set to exit US-based life science research tool developer Unchained Labs in a $435m acquisition by private equity firm Carlyle Group agreed yesterday. Unchained Labs provides a range of life science tools used by biologics and gene therapy researchers to analyse and identify large, complex molecules. It has eight product lines…
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.